Pharming Group (PHAR) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Pharming Group will report Q1 2026 results before the market opens on Thursday, May 7; analysts expect EPS $0.05 and revenue $93.75M, with a conference call at 7:30 AM ET.
• In the prior quarter the company missed estimates, reporting $0.07 EPS versus $0.15 expected and revenue of $106.5M versus $111.76M, with thin profitability (net margin 0.71%, ROE 1.08%).
• Shares trade around $16.38 with a market cap of $1.16B and a 52-week range of $8.39–$21.34; analysts' consensus is a Moderate Buy with a $38.33 target price.

Pharming Group (NASDAQ:PHAR - Get Free Report) is expected to announce its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $93.75 million for the quarter. Investors can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 7, 2026 at 7:30 AM ET.

Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings results on Thursday, March 12th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.15 by ($0.08). Pharming Group had a net margin of 0.71% and a return on equity of 1.08%. The firm had revenue of $106.50 million for the quarter, compared to analysts' expectations of $111.76 million. On average, analysts expect Pharming Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Pharming Group Stock Down 0.2%

Shares of NASDAQ PHAR opened at $16.38 on Thursday. Pharming Group has a one year low of $8.39 and a one year high of $21.34. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.59 and a quick ratio of 2.03. The business's fifty day moving average price is $16.39 and its 200-day moving average price is $16.52. The stock has a market capitalization of $1.16 billion, a PE ratio of 1,638.00 and a beta of 0.05.

Analysts Set New Price Targets

A number of research analysts have recently commented on PHAR shares. Weiss Ratings raised Pharming Group from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Monday. Oppenheimer reaffirmed an "outperform" rating and set a $41.00 price target (down from $42.00) on shares of Pharming Group in a research report on Friday, March 13th. Canaccord Genuity Group began coverage on Pharming Group in a report on Friday, April 10th. They set a "buy" rating and a $37.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $37.00 price objective on shares of Pharming Group in a report on Tuesday, March 24th. Finally, Zacks Research raised Pharming Group from a "strong sell" rating to a "hold" rating in a report on Friday, April 10th. Three analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Pharming Group presently has a consensus rating of "Moderate Buy" and a consensus target price of $38.33.

Institutional Trading of Pharming Group

A number of institutional investors have recently added to or reduced their stakes in PHAR. NewEdge Advisors LLC raised its holdings in shares of Pharming Group by 11,310.3% during the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company's stock valued at $510,000 after buying an additional 28,615 shares in the last quarter. Millennium Management LLC purchased a new position in shares of Pharming Group during the 4th quarter valued at about $360,000. SmartHarvest Portfolios LLC purchased a new position in shares of Pharming Group during the 4th quarter valued at about $224,000. Finally, EverSource Wealth Advisors LLC purchased a new position in shares of Pharming Group during the 2nd quarter valued at about $32,000. Hedge funds and other institutional investors own 0.03% of the company's stock.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company's lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.